Open Access

Anti-Inflammatory mechanisms of the proteinase-activated receptor 2-inhibiting peptide in human synovial cells

  • Ta-Liang Chen1,
  • Yung-Feng Lin2,
  • Chao-Wen Cheng3,
  • Shi-Yun Chen2,
  • Ming-Thau Sheu4,
  • Ting-Kai Leung5,
  • Cheng-Hong Qin2 and
  • Chien-Ho Chen2Email author
Contributed equally
Journal of Biomedical Science201118:43

DOI: 10.1186/1423-0127-18-43

Received: 11 February 2011

Accepted: 17 June 2011

Published: 17 June 2011

Abstract

Background

Osteoarthritis (OA) is a degenerative joint disease which affects the entire joint structure, including the synovial membrane. Disease progression was shown to involve inflammatory changes mediated by proteinase-activated receptor (PAR)-2. Previous studies demonstrated that PAR-2 messenger (m)RNA and protein levels increased in OA synovial cells, suggesting that PAR-2 is a potential therapeutic target of the disease.

Methods

We designed a PAR-2-inhibiting peptide (PAR2-IP) by changing an isoleucine residue in the PAR-2-activating peptide (PAR2-AP), SLIGKV, to alanine, generating the SLAGKV peptide. We used it to test PAR-2-mediated inflammatory responses, including the expressions of cyclooxygenase (COX)-2 and matrix metalloproteinase (MMP)-1 and activation of nuclear factor (NF)-κB in human synovial cells. As a control, expressions of COX-2 and MMP-1 were induced by trypsin at both the mRNA and protein levels.

Results

The PAR2-AP increased the expression of COX-2 more dramatically than that of MMP-1. When we treated cells with the designed PAR2-IP, the trypsin-induced COX-2 level was completely inhibited at a moderate concentration of the PAR2-IP. With further examination of trypsin-induced NF-κB activation, we observed sufficient inhibitory effects of the PAR2-IP in synoviosarcoma cells and primary synovial cells from OA patients.

Conclusions

Our study suggests that the PAR2-IP inhibits trypsin-induced NF-κB activation, resulting in a reduction in inflammatory COX-2 expression in synovial cells. Application of PAR2-IP is suggested as a potential therapeutic strategy for OA.

Background

Osteoarthritis (OA) is a degenerative joint disease in which degradation of the cartilage structure is found. A recent investigation demonstrated the significant involvement of inflammatory processes in OA pathogenesis [1]. Induction of inflammatory factors, such as interleukin (IL)-1β, by hormone disruption and/or other factors was shown to contribute to the disease progression [2, 3].

Studies on patients and a mouse model demonstrated a key role of proteinase-activated receptor (PAR)-2 in mediating arthritic inflammation [47]. PARs belong to the G-protein coupled receptor family that is activated by serine protease-mediated cleavage of the N-terminus of the receptors [8, 9]. Mounting evidence indicated that trypsin cleaves PAR-2 at R34↓S35LIGKV (in human) to expose a hexameric-tethered peptide that binds to conserved regions in the extracellular second loop of the receptor to initiate signaling [10]. The synthetic peptide (PAR2-AP) corresponding to the tethered ligand domain, SLIGKV, mimics the effects of trypsin in cell lines that naturally express PAR-2. Studies also showed that secreted proinflammatory cytokines up-regulate expression of PAR-2, stimulating more secretion of proinflammatory cytokines and metalloproteinases to enhance inflammatory responses [7, 11, 12]. When activated, PAR-2 is coupled to nuclear factor (NF)-κB activation in cells [13].

NF-κB is a sequence-specific transcription factor that regulates expressions of numerous genes, including cyclooxygenase (COX)-2 and matrix metalloproteinases (MMPs) [14, 15]. NF-κB is constitutively present in cells as a heterodimer, consisting of a p50 DNA-binding subunit and a p65 transactivating subunit. NF-κB is normally found in the cytoplasm in an inactivated state by binding to an inhibitor, such as IκBα. NF-κB activation in response to proinflammatory stimuli involves phosphorylation of IκBα, leading to its proteasomal degradation, which enables NF-κB transcription factors to be translocated to the nucleus [16, 17]. Optimal induction of NF-κB target genes also requires phosphorylation of NF-κB proteins, such as p65, in response to distinct stimuli [14].

COX-2 is the key enzyme regulating the production of prostaglandin E2 (PGE2), a central mediator of inflammation. In articular chondrocytes, proinflammatory cytokines such as IL-1β and tumor necrosis factor (TNF)-α synergistically induce COX-2 [18]. Recently, the expression of COX-2 was shown to be induced by the activation of PAR-2 through bacterial infection, or the treatment of either trypsin or PAR2-AP, and mediated inflammation in some cell types [19, 20]. Inhibition of COX-2 antagonized trypsin-induced PAR-2-dependent itching in an animal model [21].

MMPs mediate cartilage degradation by specifically cleaving matrix proteins [22]. Studies showed that IL-1β also induces expressions of MMPs [23, 24]. There is extensive evidence that among MMPs, MMP-1 (collagenase 1), MMP-3 (stromelysin 1), and MMP-13 (collagenase 3) are particularly involved in the OA process [25, 26]. Recent study indicated that activation of PAR-2 with the activating peptide induced a significant up-regulation of MMP-1 in bone osteoblasts [27].

Our previous study showed that PAR-2 is expressed in OA synovial cells without stimulation [12]. Treatment with IL-1β increased PAR-2 expression, which can be repressed by transforming growth factor (TGF)-β through multiple pathways in those cells. To further investigate how PAR-2 can be a potential therapeutic target of osteoarthritis (OA), we designed a PAR-2-inhibiting peptide (PAR2-IP) by replacing an isoleucine residue in the PAR2-AP with alanine, generating the SLAGKV peptide. When synovial cells were treated with the PAR2-IP, trypsin-induced NF-κB activation was inhibited, and the COX-2 level was reduced. Herein, we tested an effective PAR-2-inhibiting peptide, in the hopes of providing a potential therapeutic strategy for OA.

Methods

Cell culture

Human synovial cells and chondrocytes were isolated from patients undergoing joint replacement surgery [3, 12]. Tissues were cut into pieces (2~3 mm3). Chondrocytes and synovial cells were released from articular tissues by sequential incubation with 0.1% hyaluronidase (Sigma, St. Louis, Mo, USA) for 15 min, 0.5% proteinase for 30 min, and 0.2% collagenase (Sigma) for 12 h at 37°C in Dulbeccok's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY, USA). After isolation, chondrocytes and synovial cells were individually resuspended in DMEM containing 10% fetal bovine serum (FBS), a 1% penicillin-streptomycin solution, a 1% amphotericin B solution, and 1% L-glutamine, and then incubated at 37°C with 5% CO2. The media were changed every 3~4 days.

A human synoviosarcoma fibroblast-like synovium cell line, SW982, was cultured in 60-mm diameter dishes in Leibovitz's L-15 medium containing 15% FBS, a 1% penicillin-streptomycin solution, a 1% amphotericin B solution, and 1% L-glutamine at 37°C without CO2. The medium was replaced every 1~2 days.

Cell treatments

When cells reached 80% confluence, they were treated with various concentrations of stimulants for a certain time period in serum-free medium for the dose-dependent analysis, or they were treated with a specific concentration of stimulants for various time periods for the time-course analysis. Trypsin was purchased from Gibco. IL-1β was from R&D Systems, Inc. PAR2-AP and PAR2-IP were from Genemed Synthsis, Inc. PAR2-IP was designed by replacing the isoleucine residue in PAR2-AP (SLIGKV) with alanine, generating the SLAGKV peptide.

RNA extraction and polymerase chain reaction (PCR)

To evaluate the messenger (m)RNA levels of COX-2 and MMP-1, total RNA was extracted from SW982 cells using the Trizol reagent (Invitrogen). Reverse transcription was performed using the oligo dT18 primer and MMLV-derived reverse transcriptase as described elsewhere [12].

PCR primers for amplification of specific complementary (c)DNAs were synthesized according to the following oligonucleotide sequences: COX-2 sense, 5'-AAACCTCAGCTCAGGACTGC-3' and antisense, 5'-GGCACTAGCCTCTTTGCATC-3'; MMP-1 sense, 5'-GTCAGGGGAGATCATCGG-3' and antisense, 5'-GCCCAGTACTTATTCCCT-3'; and GAPDH sense, 5'-CAAGGCTGAGAACGGGAAGC-3' and antisense, 5'-AGGGGGCAGAGATGATGACC-3'. The PCR was carried out with 2 μl of template cDNA and 23 μl of PCR buffer containing each primer (0.2 μM), dNTP (2.5 mM), and Taq DNA polymerase (1.25 units) (Takara Bio Inc, Japan). In each PCR, 30 cycles of 30 s at 94°C, 30 s at a primer-specific annealing temperature, and 30 s at 72°C were performed in a Creacon Technology PCR System (Southern Africa). The RNA level of GAPDH was determined in every sample as an internal control. After amplification, the products were visualized by electrophoresis on a 2% agarose gel, stained with ethidium bromide, and illuminated with a UV lamp.

Cell lysate preparation

Whole-cell lysates were obtained from SW982 and primary synovial cells. Cells were washed with PBS, and then lysed in 50 μl of golden lysis buffer containing 20 mM Tris/HCl (pH 7.9), 137 mM NaCl, 5 mM EDTA, 1 mM EGTA, 10 mM NaF, 1 mM sodium orthovanadate, 1 mM sodium pyrophosphate, 0.1 mM β-glycerophosphate, 2 mM phenylmethylsulfo-nylfluoride (PMSF), 0.8 nM aprotinin,10 nM leupeptin, and 5 mM dithiothreitol. Protein concentrations were determined using a Bio-rad assay.

Western blotting

Equal amounts of whole-cell lysates were analyzed on 10% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, proteins were transferred to polyvinylidene difluoride (PVDF)-nylon membranes. The membranes were blocked with TBST containing 3% bovine serum albumin (BSA) at room temperature for 1 h, and then incubated with primary antibodies against COX-2 (Millipore) at 1:500, MMP-1 (Chemicon, Inc) at 1:1000, IκBα (Santa Cruz Biotechnology) at 1:1000, phosphorylated (p)-p65 (Cell signaling technology) at 1:1000, and GAPDH (Zymed) at 1:1000 in TBST overnight at 4°C. After being washed with TBST three times, the membranes were incubated with secondary antibodies at 1:10,000 in TBST at room temperature for 1 h. After another three washes, membranes were visualized using an enhanced chemiluminescence detection system (GE Healthcare).

Statistical analysis

Densities of bands on the gels were quantified by Image J (NIH, USA). Results were normalized to the amount of GAPDH. The mean and standard deviation were used to evaluate COX-2 and MMP-1 expression levels. Student's t-test was used for the comparison. The effects of stimulation by trypsin, cytokines, and PAR2-AP on COX-2 and MMP-1 expression levels were analyzed as changes relative to an unstimulated baseline. These analyses were performed individually at least three times. Statistical significance was set to p < 0.05.

Results

Trypsin induced COX-2 and MMP-1 expressions

Trypsin cleaves PAR-2 and activates inflammatory responses, but it is not clear how COX-2 and MMP-1 expressions are involved in this process in OA patient's cartilage. Therefore, we analyzed trypsin-induced COX-2 and MMP-1 expressions in human primary chondrocytes and synovial cells isolated from patients undergoing joint replacement surgery. Trypsin at 30 nM was able to increase COX-2 and MMP-1 protein levels within 3 h in both cell types; however, the effect was more obvious in synovial cells (Figure 1A, B). This is consistent with higher PAR-2 expression in synovial cells than in chondrocytes reported by a previous study [12]. A further experiment using different concentrations of trypsin demonstrated its dose-dependent effect on COX-2 protein levels in primary synovial cells (Figure 1C).
Figure 1

Induction of cyclooxidase-2 (COX-2) and matrix metalloproteinase-1 (MMP-1) expression by trypsin in human primary cells. Human primary cells were cultured as described in Materials and Methods. COX-2 and MMP-1 expression levels after trypsin treatment were analyzed by western blotting. Chondrocytes (A) and synovial cells (B) were treated with 30 nM trypsin in serum-free DMEM for different time periods as indicated. (C) Primary synovial cells were treated with various concentrations of trpsin for 8 hours.

We then used the human synoviosarcoma SW982 cell line as a model to examine trypsin-induced COX-2 and MMP1 expressions. Similarly we observed an increased COX-2 protein level by 30 nM trypsin within 3 h of incubation in this cell line (Figure 2A). We found that both the mRNA (Figure 2B) and protein (Figure 2C) levels of COX-2 and MMP-1 increased with trypsin treatment, suggesting that trypsin indeed induced the expressions of these two proteins. Dose-dependent effects of trypsin also suggested a close relationship between the trypsin substrate, PAR-2, and the inflammatory genes, COX-2 and MMP-1.
Figure 2

Induction of cyclooxidase-2 (COX-2) and matrix metalloproteinase-1 (MMP-1) expression by trypsin in human synoviosarcoma cells. Human synoviosarcoma SW982 cells were treated with trypsin in serum-free L15 medium. COX-2, MMP-1 and GAPDH expressions were assayed by western blotting and RT-PCR. Relative COX-2 and MMP-1 levels were calculated by normalizing the band densities to that of GAPDH and setting the zero controls as 100%. (A) Cells were treated with 30 nM trypsin for different time periods. COX-2 and GAPDH proteins were assayed by western blotting. (B) After trypsin treatment for 8 hours, COX-2, MMP-1 and GAPDH mRNAs in the cells were analyzed by RT-PCR and agarose gel electrophoresis, and then quantified. (C) After trypsin treatment for 8 hours, COX-2, MMP-1 and GAPDH protein levels in the cells were analyzed and quantified.

PAR2-AP stimulated COX-2 and MMP-1 expressions in synovial cells

In chondrocytes, PAR-2 activation by the activating peptide (PAR2-AP), SLIGKV, significantly induced COX-2 and MMP-1 expressions [4]. To test whether the PAR2-AP produces the same effect in synovial cells, we treated SW982 cells with this PAR2-AP at different concentrations for 24 h, and then analyzed COX-2 and MMP-1 protein levels. As a control, IL-1β, which was shown to upregulate PAR-2 expression, increased both COX-2 and MMP-1 levels in cells, suggesting a close correlation between PAR-2 and these two inflammatory proteins (Figure 3A). The PAR2-AP at ≥ 50 μM significantly increased the COX-2 level, but had less effect on MMP-1.
Figure 3

Induction of cyclooxidase-2 (COX-2) and matrix metalloproteinase-1 (MMP-1)expression by proteinase-activated receptor-2-activating peptide (PAR2-AP) in human synoviosarcoma cells. Human synoviosarcoma SW982 cells were starved in serum-free L15 medium and treated with the PAR2-AP, IL-1β, and/or trypsin. Expressions of COX-2 and MMP-1 were analyzed by western blotting, and relative levels were calculated by normalizing the band densities to that of GAPDH and setting the zero controls as 100%. (A) Cells were treated with IL-1β at 5 ng/ml or PAR-2 AP at different concentrations for 24 hours after 12 hours of starvation. (B) Cells were pretreated with PAR2-AP at different concentrations for 30 minutes and then incubated with trypsin at 30 nM for 6 hours.

The addition of trypsin to the cells, pretreated with the PAR2-AP, further enhanced the COX-2 level (Figure 3B). These results indicate that PAR-2 activation by PAR2-AP and trypsin leads to COX-2 expression, and PAR2-AP and trypsin had additive effects on this reaction. To our surprise, COX-2 may be more important than MMP-1 in PAR-2-mediated responses in synovial cells.

The PAR2-IP inhibited trypsin-induced COX-2 expression

Effects of the PAR2-IP, SLAGKV, on COX-2 and MMP-1 expressions were also evaluated in SW982 synoviosarcoma cells. When treated with the PAR2-IP, cell responses were similar to those with the PAR-AP, but they seemed reduced with PAR2-IP treatment (Figures 3A, 4A).
Figure 4

Inhibition of trypsin-induced cyclooxidase-2 (COX-2) expression by proteinase-activated receptor-2-inhibiting peptide (PAR2-IP) in human synoviosarcoma cells. Human synoviosarcoma SW982 cells were treated with the PAR2-IP, IL-1β, and/or trypsin in serum-free L15 medium. Expressions of COX-2 and MMP-1 were analyzed by western blotting, and relative levels were calculated by normalizing the band densities to that of GAPDH and setting the zero controls as 100%. (A) Cells were treated with IL-1β at 5 ng/ml or PAR-2 AP at different concentrations for 24 hours. (B) Cells were pretreated with PAR2-AP at different concentrations for 30 minutes and then incubated with trypsin at 30 nM for 6 hours.

Since our experiments showed that trypsin induced COX-2 expression (Figures 1, 2), and PAR2-AP pretreatment further increased its level in cells (Figure 3), we examined the effects of the PAR2-IP on changes in trypsin-induced COX-2 expression. It is plausible that the induction was reduced by the additional PAR2-IP in a dose-dependent manner (Figure 4B). The result suggests that the designated PAR2-IP inhibits trypsin-induced COX-2-dependent inflammatory responses in synovial cells.

The PAR2-IP inhibited trypsin-induced NF-κB activation

It was shown that activated PAR-2 is coupled to NF-κB activation in cells [13], and NF-κB is involved in COX-2 transcriptional activation [14]. We then tested whether the PAR2-IP interferes with NF-κB activation. In control experiments using primary and SW982 synovial cells, treatment with 60 nM trypsin resulted in marked hosphorylation of p65, an activated form of NF-κB, and degradation of IκBα, an inhibitor of NF-κB (Figure 5A). When cells were treated with PAR2-IP alone, phosphorylated p65 levels also increased, a phenomenon that is consistent with the idea that PAR2-IP alone may mimic PAR2-AP on PAR-2 signaling, as seen in Figure 4A. After pretreatment of cells with the PAR2-IP at 75 μM, the trypsin-induced phosphorylation of p65 was inhibited in both cell types (Figure 5B). These results suggest that the PAR2-IP inhibited trypsin-induced activation of NF-κB, which regulates COX-2 expression and inflammatory responses in human synovial cells.
Figure 5

Inhibition of trypsin-induced nuclear factor (NF)-κB activation by proteinase-activated receptor-2-inhibiting peptide (PAR2-IP) in synovial cells. Human primary synovial cells or synoviosarcoma SW982 cells were treated with trypsin and/or PAR2-IP, and the levels of phospho-p65 (p-p65), an activated NF-κB, and/or IκBα, an NF-κB inhibitor, were analyzed by western blotting. (A) Cells were incubated in serum-free DMEM medium (for primary cells) or L15 medium (for SW982 cells), and then treated with 60 nM trypsin for 15, 30, 60 and 120 minutes. (B) Cells were treated with 75 μM PAR2-IP or 60 nM trypsin alone for 30 minutes, or in combination with adding PAR2-IP first for 30 minutes and then trypsin for another 30 minutes. The relative levels of p-p65 were calculated by normalizing the band densities to that of GAPDH and setting the controls as 100%.

Discussion

Previous studies showed that PAR2 activation results in proinflammatory effects including vasodilatation, edema, reflux esophagitis, and leukocyte-endothelial interactions [5, 2831]. It was also suggested that luminal proteases activate PAR-2 in the mouse colon to induce inflammation [31]. Following PAR-2 activation, the inflammatory markers, COX-2 and MMP-1, were upregulated in chondrocytes [4]. Our earlier study showed higher expression levels of PAR-2 in human primary synovial cells than in chondrocytes [12]. However, the role of PAR-2 in synovial cells has not been well investigated. Therefore in the present study, we investigated the effects of PAR-2 activation and inhibition of COX-2 and MMP-1 expressions in primary OA synovial cells as well as in model cells, which suggested anti-inflammatory mechanisms of the PAR2-IP.

Trypsin is well recognized as an activator of PAR2. Importantly, trypsin was able to mimic carrageenan/kaolin (C/K)-induced joint swelling, an effect that was abrogated by inhibitors of this proteolytic enzyme [32]. Although there could be a concern of trypsin-induced cell death, similar conditions were used in other studies [13, 33]. no sign of increased protein degradation in cells treated with trypsin, and the level of the marker protein, GAPDH, was consistent after trypsin treatment in our experiments. Our study demonstrated that the trypsin-PAR-2 interaction induced COX-2 and MMP-1 expressions in both OA chondrocytes and synovial cells; however, the effect on COX-2 was more obvious than MMP-1 in synovial cells (Figure 1). In primary synovial cells, trypsin induced both COX-2 and MMP-1 protein productions; however, trypsin tended to induce more COX-2 than MMP-1. Likewise this phenomenon was also seen in PAR2-AP-induced COX-2 and MMP-1 expressions (Figure 3). These results suggest that regulation of PAR-2 activity may differ between synovial cells and chondrocytes.

To design the inhibiting peptide, PAR2-IP, we change the isoleucine residue in the PAR2-AP to alanine, generating the SLAGKV peptide. With one residue modification, this peptide has similar effects on PAR-2 signaling; however, it inhibited trypsin-induced COX-2 expression in a dose-dependent manner (Figure 4B). The effect of trypsin was entirely eliminated by PAR2-IP at a moderate concentration (50 μM), suggesting a specific interaction between PAR2-IP and trypsin. Similar phenomena were also seen in trypsin-induced NF-κB activation (Figure 5B). It is known that the sequence of PAR2-AP is identical to trypsin-digested N-terminal PAR-2, and they bind to the same region of PAR2 [10, 34]. In other words, PAR2-AP is able to bind trypsin, however, without interference on its activity. Indeed, PAR2-AP and trypsin had additive effects to promote COX-2 expression in the cells (Figure 3B). In the contrary, PAR2-IP may bind to trypsin with high affinity, and consequently inhibits its digesting activity.

Recent studies have demonstrated that trypsin- and PAR2-AP-activated PAR-2 induces inflammatory responses through p65 NF-κB pathway in many cell types. Electrophoretic mobility shift assays, reporter gene assays, and morphological ransduction studies revealed PAR-2-induced activation and translocation of NF-κB in human keratinocytes [13, 35]. PAR-2 agonists also activated p65-NF-κB in endothelial and epithelial cells [36, 37]. Similarly we found that trypsin activated NF-κB in human synovial cells (Figure 5A). Furthermore our data demonstrated inhibitory effect of PAR2-IP on trypsin-induced activation of NF-κB, and down-regulation of inflammatory COX-2 expression in human synoviosarcoma and primary OA synovial cells.

It was shown that activation of PAR-2 results in proinflammatory reactions via the production of cytokines, such as IL-6, IL-8, and prostaglandin [38, 39]. It was also reported that PAR-2 activation induces production of IL-1β and Inter-Cellular Adhesion Molecule (ICAM)-1 by lung epithelial and umbilical vein endothelial cells [40]. Those reports suggested that PAR-2 activation may be associated with local increases in serine proteases that induce cytokine-related inflammation. Although further studies may be required to discover detailed mechanisms, application of PAR2-IP is suggested as a potential therapeutic strategy for OA.

Conclusions

Our findings suggest that this PAR2-IP inhibits trypsin-induced PAR-2 activation, and represses NF-κB activity, resulting in a reduction in inflammatory COX-2 levels in synovial cells. This is a novel finding that a PAR2-IP can repress NF-κB activation and COX-2 expression. Herein we demonstrated a potential application of a PAR-2 inhibitory strategy that may slow down the OA disease progression and reduce patient symptoms.

Disclosure of Potential Conflicts of interests

The authors declare that they have no competing interests.

Notes

Abbreviations

OA: 

osteoarthritis

PAR: 

proteinase-activated receptor

PAR2-AP: 

PAR-2-activating peptide

PAR2-IP: 

PAR-2-inhibiting peptide

COX: 

cyclooxygenase

NF: 

nuclear factor

IKK: 

IκB kinase

MMP: 

matrix matelloproteinase

IL: 

interleukin

TNF: 

tumor necrosis factor

TGF: 

transforming growth factor.

Declarations

Acknowledgements and Funding

We appreciate the financial support from the National Science Council of Taiwan (NSC98-2314-B-038-005-MY3) and Taipei Medical University Hospital (96TMU-TMUH-10).

Authors’ Affiliations

(1)
Department of Anesthesiology, Taipei Medical University Hospital
(2)
School of Medical Laboratory Science and Biotechnology, Taipei Medical University
(3)
Graduate Institute of Clinical Medicine, Taipei Medical University
(4)
Graduate Institute of Pharmaceutical Sciences, Taipei Medical University
(5)
Department of Diagnostic Radiology, Taipei Medical University Hospital

References

  1. Pelletier J-P, Martel-Pelletier J, Abramson SB: Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targets. Arthritis & Rheumatism. 2001, 44: 1237-1247. 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F.View ArticleGoogle Scholar
  2. Goldring MB: Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep. 2000, 2: 459-465. 10.1007/s11926-000-0021-y.View ArticlePubMedGoogle Scholar
  3. Wang KC, Lin YF, Qin CH, Chen TL, Chen CH: Bisphenol-A interferes with estradiol-mediated protection in osteoarthritic chondrocytes. Toxicol Lett. 2010, 198: 127-133. 10.1016/j.toxlet.2010.06.007.View ArticlePubMedGoogle Scholar
  4. Boileau C, Amiable N, Martel-Pelletier J, Fahmi H, Duval N, Pelletier JP: Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Res Ther. 2007, 9: R121-10.1186/ar2329.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Busso N, Frasnelli M, Feifel R, Cenni B, Steinhoff M, Hamilton J, So A: Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum. 2007, 56: 101-107. 10.1002/art.22312.View ArticlePubMedGoogle Scholar
  6. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, Smith AJ, Hunter GD, McLean JS, McGarry F: Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest. 2003, 111: 35-41.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Xiang Y, Masuko-Hongo K, Sekine T, Nakamura H, Yudoh K, Nishioka K, Kato T: Expression of proteinase-activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1beta, TNF-alpha and TGF-beta. Osteoarthritis Cartilage. 2006, 14: 1163-1173. 10.1016/j.joca.2006.04.015.View ArticlePubMedGoogle Scholar
  8. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J: Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA. 1994, 91: 9208-9212. 10.1073/pnas.91.20.9208.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Vu TK, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991, 64: 1057-1068. 10.1016/0092-8674(91)90261-V.View ArticlePubMedGoogle Scholar
  10. Dery O, Corvera CU, Steinhoff M, Bunnett NW: Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998, 274: C1429-1452-Google Scholar
  11. L'Hermette MF, Tourny-Chollet C, Polle G, Dujardin FH: Articular cartilage, degenerative process, and repair: current progress. Int J Sports Med. 2006, 27: 738-744. 10.1055/s-2005-872824.View ArticlePubMedGoogle Scholar
  12. Tsai SH, Sheu MT, Liang YC, Cheng HT, Fang SS, Chen CH: TGF-beta inhibits IL-1beta-activated PAR-2 expression through multiple pathways in human primary synovial cells. J Biomed Sci. 2009, 16: 97-10.1186/1423-0127-16-97.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Goon Goh F, Sloss CM, Cunningham MR, Nilsson M, Cadalbert L, Plevin R: G-protein-dependent and -independent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytes. Cell Signal. 2008, 20: 1267-1274. 10.1016/j.cellsig.2008.02.015.View ArticlePubMedGoogle Scholar
  14. Viatour P, Merville MP, Bours V, Chariot A: Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci. 2005, 30: 43-52. 10.1016/j.tibs.2004.11.009.View ArticlePubMedGoogle Scholar
  15. Vincenti MP, Brinckerhoff CE: Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002, 4: 157-164. 10.1186/ar401.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994, 12: 141-179. 10.1146/annurev.iy.12.040194.001041.View ArticlePubMedGoogle Scholar
  17. Grimm S, Baeuerle PA: The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits. Biochem J. 1993, 290 (Pt 2): 297-308.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Fitzpatrick FA: Cyclooxygenase enzymes: regulation and function. Curr Pharm Des. 2004, 10: 577-588. 10.2174/1381612043453144.View ArticlePubMedGoogle Scholar
  19. Lundy FT, About I, Curtis TM, McGahon MK, Linden GJ, Irwin CR, El Karim IA: PAR-2 Regulates Dental Pulp Inflammation Associated with Caries. Journal of Dental Research. 2010, 89: 684-688. 10.1177/0022034510365652.View ArticlePubMedGoogle Scholar
  20. Seo JH, Kim KH, Kim H: Role of Proteinase-Activated Receptor-2 on Cyclooxygenase-2 Expression in H. pylori-Infected Gastric Epithelial Cells. Annals of the New York Academy of Sciences. 2007, 1096: 29-36. 10.1196/annals.1397.067.View ArticlePubMedGoogle Scholar
  21. Costa R, Marotta DM, Manjavachi MN, Fernandes ES, Lima-Garcia JF, Paszcuk AF, Quintão NLM, Juliano L, Brain SD, Calixto JB: Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice. British Journal of Pharmacology. 2008, 154: 1094-1103. 10.1038/bjp.2008.172.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Mort JS, Billington CJ: Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res. 2001, 3: 337-341. 10.1186/ar325.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Moos V, Fickert S, Muller B, Weber U, Sieper J: Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol. 1999, 26: 870-879.PubMedGoogle Scholar
  24. Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, Abramson SB, Amin AR: Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem. 2000, 275: 40307-40315. 10.1074/jbc.M002721200.View ArticlePubMedGoogle Scholar
  25. Tetlow LC, Adlam DJ, Woolley DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001, 44: 585-594. 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
  26. Mengshol JA, Mix KS, Brinckerhoff CE: Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark?. Arthritis Rheum. 2002, 46: 13-20. 10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
  27. Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier J-P, Martel-Pelletier J, Boileau C: Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts. Bone. 2009, 44: 1143-1150. 10.1016/j.bone.2009.02.015.View ArticlePubMedGoogle Scholar
  28. Saifeddine M, al-Ani B, Cheng CH, Wang L, Hollenberg MD: Ratproteinase-activated receptor-2 (PAR-2): cDNA sequence and activity ofreceptor-derived peptides in gastric and vascular tissue. Br J Pharmacol. 1996, 118: 521-530.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL: Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol. 1999, 127: 1083-1090. 10.1038/sj.bjp.0702634.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Yoshida N, Katada K, Handa O, Takagi T, Kokura S, Naito Y, Mukaida N, Soma T, Shimada Y, Yoshikawa T, Okanoue T: Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Mol Med. 2007, 19: 335-340.PubMedGoogle Scholar
  31. Vergnolle N: Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. J Immunol. 1999, 163: 5064-5069.PubMedGoogle Scholar
  32. Kelso EB, Lockhart JC, Hembrough T, Dunning L, Plevin R, Hollenberg MD, Sommerhoff CP, McLean JS, Ferrell WR: Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther. 2006, 316: 1017-1024.View ArticlePubMedGoogle Scholar
  33. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, Kahn M, Nelken NA, Coughlin SR, Payan DG, Bunnett NW: Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996, 314: 1009-1016.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Holzhausen M, Spolidorio L, Vergnolle N: Role of protease-activated receptor-2 in inflammation, and its possible implications as a putative mediator of periodontitis. Memórias do Instituto Oswaldo Cruz. 2005, 100: 177-180.View ArticlePubMedGoogle Scholar
  35. Buddenkotte J, Stroh C, Engels IH, Moormann C, Shpacovitch VM, Seeliger S, Vergnolle N, Vestweber D, Luger TA, Schulze-Osthoff K, Steinhoff M: Agonists of Proteinase-Activated Receptor-2 Stimulate Upregulation of Intercellular Cell Adhesion Molecule-1 in Primary Human Keratinocytes via Activation of NF-kappa B. J Investig Dermatol. 2004, 124: 38-45.View ArticleGoogle Scholar
  36. Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, Wheeler-Jones CPD: Cyclooxygenase-2 Induction and Prostacyclin Release by Protease-activated Receptors in Endothelial Cells Require Cooperation between Mitogen-activated Protein Kinase and NF-κB Pathways. Journal of Biological Chemistry. 2006, 281: 11792-11804. 10.1074/jbc.M509292200.View ArticlePubMedGoogle Scholar
  37. Wang H, Moreau F, Hirota CL, MacNaughton WK: Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation. The FASEB Journal. 2010, 24: 1971-1980. 10.1096/fj.09-137646.View ArticlePubMedGoogle Scholar
  38. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, Stewart GA: Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol. 2002, 168: 3577-3585.View ArticlePubMedGoogle Scholar
  39. Johansson U, Lawson C, Dabare M, Syndercombe-Court D, Newland AC, Howells GL, Macey MG: Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-1{beta}. J Leukoc Biol. 2005, 78: 967-975. 10.1189/jlb.0704422.View ArticlePubMedGoogle Scholar
  40. Compton SJ, Cairns JA, Holgate ST, Walls AF: The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1 beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J Immunol. 1998, 161: 1939-1946.PubMedGoogle Scholar

Copyright

© Chen et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.